Evidence map›Paper›PMID 37846985›Full record

ArticleJournal of virology2023

Diet-induced obesity and diabetes enhance mortality and reduce vaccine efficacy for SARS-CoV-2.

Robert M Johnson, Jeremy Ardanuy, Holly Hammond, James Logue, Lian Jackson, Lauren Baracco, Marisa McGrath, Carly Dillen, Nita Patel, Gale Smith and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Robert M JohnsonCenter for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine , Baltimore, Maryland, USA.
Jeremy ArdanuyCenter for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine , Baltimore, Maryland, USA.
Holly HammondCenter for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine , Baltimore, Maryland, USA.
James LogueCenter for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine , Baltimore, Maryland, USA.
Lian JacksonCenter for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine , Baltimore, Maryland, USA.
Lauren BaraccoCenter for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine , Baltimore, Maryland, USA.
Marisa McGrathCenter for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine , Baltimore, Maryland, USA.
Carly DillenCenter for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine , Baltimore, Maryland, USA.
Nita PatelNovavax , Gaithersburg, Maryland, USA.
Gale SmithNovavax , Gaithersburg, Maryland, USA.
Matthew FriemanCenter for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine , Baltimore, Maryland, USA.ORCID 0000-0003-0107-0775
University of Maryland, Baltimore · USNovavax (United States) · US

Funding

FELLOWSHIP TRAINING PROGRAM IN VACCINOLOGYT32AI007524 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Marcelo B. Sztein · 1997 to 2026
$6.4M
Role of Diabetes in MERS Coronavirus PathogenesisR01AI148166 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI FRIEMAN, MATTHEW BRYAN · 2020 to 2023
$2.3M
Diabetic Comorbidity and MERS Coronavirus PathogenesisR21AI126300 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI FRIEMAN, MATTHEW BRYAN · 2016 to 2017
$429k
NIAID NIH HHS HHSN272201400007CNIAID NIH HHS HHSN272201400008CNIAID NIH HHS R01 AI148166NIAID NIH HHS R21 AI126300NIAID NIH HHS T32 AI007524
6 · The paper itself

Abstract

importanceSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a wide spectrum of diseases in the human population, from asymptomatic infections to death. It is important to study the host differences that may alter the pathogenesis of this virus. One clinical finding in coronavirus disease 2019 (COVID-19) patients is that people with obesity or diabetes are at increased risk of severe illness from SARS-CoV-2 infection. We used a high-fat diet model in mice to study the effects of obesity and type 2 diabetes on SARS-CoV-2 infection as well as how these comorbidities alter the response to vaccination. We find that diabetic/obese mice have increased disease after SARS-CoV-2 infection and they have slower clearance of the virus. We find that the lungs of these mice have increased neutrophils and that removing these neutrophils protects diabetic/obese mice from disease. This demonstrates why these diseases have increased risk of severe disease and suggests specific interventions upon infection.

Indexed as

COVID-19 VaccinesDiabetes Mellitus, Type 2ObesityVaccine EfficacyAnimalsCOVID-19DietHumansMiceMice, ObeseSARS-CoV-2COVID-19 Vaccinescoronavirusdiabetesimmunization

Identifiers

PMID37846985
PMCPMC10688338
OpenAlexW4387692361

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.